Raymond James Financial
TSHA icon

Raymond James Financial’s Taysha Gene Therapies TSHA Stock Holding History

Raymond James Financial’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
166,042
+144,011
+654% +$852K ﹤0.01% 3910
2026
Q1 		$98.5K Buy
22,031
+3,887
+21% +$18.1K ﹤0.01% 5034
2025
Q4 		$99.8K Buy
+18,144
New +$88.1K ﹤0.01% 4925
2025
Q3 		– Sell
-3,605
Closed -$8.33K – 6647
2025
Q2 		$8.33K Buy
+3,605
New +$7.83K ﹤0.01% 5994

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Raymond James Financial's TSHA Position: Q2 2026 in Review

Raymond James Financial increased its Taysha Gene Therapies (TSHA) stake by 654% in Q2 2026, buying an estimated $852K and bringing the position to 166,042 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3910.

Raymond James Financial first reported a position in TSHA in Q2 2025 and has held it in 4 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Raymond James Financial held 166,042 shares of Taysha Gene Therapies worth $1.13M as of Q2 2026.
  • Raymond James Financial bought 144,011 Taysha Gene Therapies shares in Q2 2026, an estimated $852K.
  • Taysha Gene Therapies made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3910 holding.
  • Raymond James Financial first reported a position in Taysha Gene Therapies in Q2 2025 and has held it in 4 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.